The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group.
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative, established by the National Office of Public Health Genomics at the Centers for Disease Control and Prevention, supports the development and implementation of a rigorous, evidence-based process for evaluating genetic tests and other genomic applications for clinical and public health practice in the United States. An independent, non-federal EGAPP Working Group (EWG), a multidisciplinary expert panel selects topics, oversees the systematic review of evidence, and makes recommendations based on that evidence. This article describes the EGAPP processes and details the specific methods and approaches used by the EWG.
Teutsch
Steven M
SM
Merck & Company, Inc., West Point, Pennsylvania, USA.
Bradley
Linda A
LA
Palomaki
Glenn E
GE
Haddow
James E
JE
Piper
Margaret
M
Calonge
Ned
N
Dotson
W David
WD
Douglas
Michael P
MP
Berg
Alfred O
AO
D002487:Centers for Disease Control and Prevention, U.S.; D005069:Evaluation Studies as Topic; D019317:Evidence-Based Medicine / Q000379:methods*; D005821:Genetic Techniques / Q000592:standards; D005826:Genetics, Medical / Q000379:methods* / Q000639:trends; D023281:Genomics / Q000379:methods*; D006801:Humans; D014481:United States